Stockscreener 앱 받기
70.70
0.31%
-0.22
시간 외 거래:
67.00
-3.70
-5.23%
전일 마감가:
$70.92
열려 있는:
$71.19
하루 거래량:
846.06K
Relative Volume:
0.55
시가총액:
$5.68B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-11.90
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
-2.29%
1개월 성능:
-8.88%
6개월 성능:
+56.17%
1년 성능:
+44.49%
1일 변동 폭
$69.96
$71.92
1주일 범위
$69.75
$75.00
52주 변동 폭
$35.95
$87.50
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
70.70 | 5.69B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
PTC Therapeutics Withdraws Translarna NDA After FDA Feedback - TipRanks
PTC Therapeutics falls after withdrawing muscle disorder drug marketing application - TradingView
PTC Therapeutics stock falls after withdrawing Translarna drug application By Investing.com - Investing.com Canada
FDA skepticism ends PTC bid to market Duchenne drug Translarna in U.S. - Stock Titan
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
PTC Therapeutics (NASDAQ:PTCT) Shareholders Have Earned a 18% CAGR Over the Last Three Years - 富途牛牛
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU - MSN
Price Action: How does Guardian Pharmacy Services Inc correlate with NasdaqTrade Risk Assessment & Safe Entry Point Alerts - baoquankhu1.vn
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation - ChartMill
PTC Therapeutics, Inc. $PTCT Stock Position Decreased by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 - Finviz
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
Understanding Momentum Shifts in (PTCT) - Stock Traders Daily
Tech Rally: Is PTC Therapeutics Inc a stock for growth or value investorsJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
WCM Investment Management LLC Acquires Shares of 147,065 PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Investor Outlook: An 18% Upside Potential Amidst Robust Pipeline - DirectorsTalk Interviews
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup - Chartmill
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Meme Stocks: What is PTC Therapeutics Inc.’s book value per shareEarnings Overview Summary & Growth Focused Entry Reports - baoquankhu1.vn
Evaluating PTC Therapeutics (PTCT) Valuation After Barclays Rating Upgrade And Growing Analyst Confidence - Yahoo Finance
Converging Analyst Upgrades on PTC’s Rare Disease Pipeline Might Change The Case For Investing In PTC Therapeutics (PTCT) - Sahm
Barclays Upgrades PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Sees Analyst Rating Upgrade to Overweigh - GuruFocus
PTC Therapeutics stock initiated with Overweight rating at Barclays By Investing.com - Investing.com Canada
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Potential Upside with Innovative Rare Disorder Treatments - DirectorsTalk Interviews
A Look At PTC Therapeutics (PTCT) Valuation After New 2026 Revenue Guidance And Morgan Stanley Support - Sahm
Sector Gamma AS Increases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Avoiding Lag: Real-Time Signals in (PTCT) Movement - Stock Traders Daily
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves - Finviz
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Momentum Shift: What is International Money Express Incs market positionTrade Exit Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
First Week of September 18th Options Trading For PTC Therapeutics - Nasdaq
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)? - Sahm
Discipline and Rules-Based Execution in PTCT Response - Stock Traders Daily
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics reports $92.5M in Q4 Sephience revenue By Investing.com - Investing.com Nigeria
Lobbying Update: $50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Ptc Therapeutics CEO Klein sells $192k in shares By Investing.com - Investing.com Nigeria
Ptc Therapeutics CEO Klein sells $192k in shares - Investing.com
Utter, SVP at Ptc Therapeutics, sells $79k in shares By Investing.com - Investing.com Canada
Pauwels Eric, chief business officer of Ptc Therapeutics, sells $566k in shares - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 4,602 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 881 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 866 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Sells $192,195.30 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 6.7%Here's Why - MarketBeat
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
PTC 테라퓨틱스 주식 (PTCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 08 '26 |
Sale |
76.50 |
4,602 |
352,057 |
82,887 |
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 09 '26 |
Sale |
77.41 |
1,722 |
133,300 |
81,165 |
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 12 '26 |
Sale |
78.70 |
1,024 |
80,589 |
80,141 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Jan 08 '26 |
Sale |
76.45 |
2,514 |
192,195 |
394,453 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Jan 08 '26 |
Sale |
76.45 |
866 |
66,206 |
92,428 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 08 '26 |
Sale |
76.56 |
4,033 |
308,760 |
113,626 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 09 '26 |
Sale |
77.93 |
2,314 |
180,320 |
111,312 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 08 '26 |
Sale |
76.45 |
881 |
67,352 |
115,196 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 08 '26 |
Sale |
76.45 |
59 |
4,511 |
6,791 |
1.24%
0.19%
자본화:
|
볼륨(24시간):